17.71
3.95 (28.71%)
AIStockmoo Score
| Value 30% | -3.9 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| Timing 30% | -2.2 |
| From our AI technical analysis of the chart. info | NA |
| Uptrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 0.2 |
| Insider Activity info | NA |
| Institutions net +0.15% of shares in their latest 13F filings: 35 holders increased, 18 decreased (quarter to 30 Sep 2026). info | |
| Short interest -5.0% from 31 Aug to 30 Oct 2026, 12.5 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Short-term trend up, medium and long-term down. Short-term momentum falling. info | |
| Price is between support and resistance. Levels trending up. info | |
| Final Score | -2.42 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Greenwich LifeSciences, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GLSI | - | - | - | 70.35 |
| GLTO | 2 B | - | - | - |
| IPA | 96 M | - | - | 5.98 |
| ACIU | - | - | - | 6.56 |
| DNLI | - | - | - | 3.24 |
| GHRS | - | - | - | 3.65 |
Select this tab to load the latest available analysis.
|
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 52.30% |
| % Held by Institutions | 9.47% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 13.79%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 35 | 189,628 |
| Decreased | 18 | 137,114 |
| New | 4 | 18,060 |
| Sold out | 7 | 48,039 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 1,578,166 | 12.5 |
| 15 Oct 2026 | 1,552,366 | 10.7 |
| 30 Sep 2026 | 1,580,950 | 11.4 |
| 15 Sep 2026 | 1,631,150 | 19.8 |
| 31 Aug 2026 | 1,660,969 | 11.4 |
| 14 Aug 2026 | 1,593,720 | 13.3 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Greenwich LifeSciences Gears Up For Two Breast Cancer Vaccine Presentations — Retail Says ‘Peptide Vaccine Works’ After SLS Trial Success
Greenwich said two research abstracts related to its experimental breast cancer drug were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11… |
| 17 Nov 2026 | Yahoo Finance |
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast… |
| 15 Sep 2026 | Yahoo Finance |
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest. |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |